Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review
ConclusionsEvidence informing the use of BMA beyond 2 years is heterogeneous and based on retrospective analysis. Prospective randomized studies with greater emphasis on quality of life are needed.PROSPERO registration numberCRD42019126813
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Orthopaedics | Prostate Cancer | Study | Toxicology | Xgeva